Revefenacin is an investigational, once-daily, nebulized long-acting muscarinic antagonist (LAMA) in development for the treatment of chronic obstructive pulmonary disease (COPD). The product candidate, which is currently being evaluated in a Phase 3 program, has successfully completed Phase 2 and Phase 2b studies demonstrating clinically meaningful improvements in lung function in COPD patients and supporting a profile appropriate for once-daily administration.
Revefenacin has the potential to be a best-in-class once-daily single-agent product for COPD patients who require, or prefer, nebulized therapy. Furthermore, the therapeutic profile of revefenacin, together with its physical characteristics, suggest that this LAMA could serve as a foundation for combination products and for delivery in metered dose inhaler and dry powder inhaler products. We have a strategic collaboration with Mylan for the development and commercialization of revefenacin.